Autoantibodies Directed Against G-Protein-Coupled Receptors in Cardiovascular Diseases: Basics and Diagnostics

The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches

Volumn , Issue , 2017, Pages 49-63

  Bornholz, Beatrice ^a   Wallukat, Gerd ^b   Roggenbuck, Dirk ^c   Schimke, Ingolf ^b  

^a Medipan GmbH   (Germany)

^b Berlin Space Technologies GmbH   (Germany)

^c BRANDENBURG UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Autoantibodies; Bioassay; Cardiomyopathy; Cardiovascular diseases; Diagnostics; ELISA; G protein coupled receptors

Indexed keywords

EID: 85020517917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-803267-1.00003-X     Document Type: Chapter

References (125)

1. Wallukat G., Nissen E., Müller J., Brinckmann R., Schimke I., Kunze R. The pathophysiological role of autoantibodies directed to G-protein coupled receptors and therapeutic strategies of antibody removal. Affina academy: G-protein coupled receptors and autoantibodies 2002, 7-47. Pabst Science Publishers, Lengerich. R. Kunze, R. Brinkmann (Eds.).
2. Xia Y., Kellems R.E. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 2011, 7:659-674.
3. Patel P.A., Hernandez A.F. Targeting anti-β1-adrenergic receptor antibodies for dilated cardiomyopathy. Eur J Heart Fail 2013, 15:724-729.
4. Luft F.C. Activating autoantibodies and cardiovascular diseases. Physiology 2013, 28:254-261.
5. Sterin-Borda L., Cossio P.M., Gimeno M.F., Gimeno A.L., Diez C., Laguens P.P., et al. Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and functional aspects. Cardiovas Res 1976, 10:613-622.
6. Venter J.C., Fraser C.M., Harrison L.C. Autoantibodies to β2-adrenergic receptors: a possible cause of adrenergic hyporesponsiveness in allergic rhinitis and asthma. Science 1980, 207:1361-1363.
7. Borda E., Pascual J., Cossio P., De la Vega M., Arana R., Sterin-Borda L. A circulating IgG in Chagas' disease which binds to ß-adrenoceptors of myocardium and modulates their activity. Clin Exp Immunol 1884, 57:679-686.
8. Wallukat G., Wollenberger A. Effects of γ globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic β adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta 1987, 46:S634-S639.
9. Magnusson Y., Marullo S., Hoyer S., Waagstein F., Andersson B., Vahlne A., et al. Mapping of a functional autoimmune epitope on the β 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990, 86:1658-1663.
10. Wallukat G., Morwinski R., Magnusson Y., Hoebeke J., Wollenberger A. Autoantibodies against the β 1-adrenergic receptor in myocarditis and dilated cardiomyopathy: localization of two epitopes. Z Kardiol 1992, 81(Suppl. 4):79-83.
11. Munoz-Saravia S.G., Haberland A., Wallukat G., Schimke I. Chronic Chagas' heart disease - from pathogenesis to treatment regimes. Appl Cardiopulm Pathophysiol 2012, 16:55-81.
12. Limas C.J., Goldenberg I.F., Limas C. Influence of anti-β receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990, 119:1322-1328.
13. Jahns R., Boivin V., Lohse M.J. β1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol 2006, 112:7-14.
14. Xia Y., Wen H., Bobst S., Day M.C., Kellems R.E. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003, 10:82-93.
15. Wallukat G., Wolleberger A. Autoantibodies to β2 adrenergic receptor with antiadrenergic activity from patients with allergic asthma. J Allergy Clin Immunol 1991, 88:581-587.
16. Gironès N., Cuervo H., Fresno M. Trypanosoma cruzi-induced molecular mimicry and Chagas' disease. Curr Top Microbiol Immunol 2005, 296:89-123.
17. Cunha-Neto E., Bilate A.M., Hyland K.V., Fonseca S.G., Kalil J., Engman D.M. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 2006, 39:41-54.
18. Levin M.J., Hoebeke J. Cross-talk between anti-β1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease. Autoimmunity 2008, 41:429-433.
19. Eftekhari P., Sallé L., Lezoualc'h F., Mialet J., Gastineau M., Briand J.P., et al. Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 2000, 30:2782-2790.
20. Kamel R., Eftekhari P., Clancy R., Buyon J.P., Hoebeke J. Autoantibodies against the serotoninergic 5HT4 receptor and congenital heart block. J Autoimmun 2005, 25:72-76.
21. Spotnitz M.D., Lesch M. Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog Cardiovasc Dis 2006, 49:42-57.
22. Mijares A., Lebesgue D., Argibay J., Hoebeke J. Anti-peptide antibodies sensitive to the active state of the β2 adrenergic receptor. FEBS Lett 1996, 399:188-191.
23. Elies R., Fu L.X., Eftekhari P., Wallukat G., Schulze W., Granier C., et al. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. Eur J Biochem 1998, 251:659-666.
24. Mijares A., Lesbesgue D., Wallukat G., Hoebeke J. From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-β(2)-adrenoceptor antibody behave as antagonist. Mol Pharmacol 2000, 58:373-379.
25. Hoebeke J. Molecular mechanisms of anti-G-protein-coupled receptor autoantibody. Autoimmunity 2001, 34:161-164.
26. Wallukat G., Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Seminars in Immunopathology 2014, 36:351-363.
27. Elias F. Detection of Trypanosoma cruzi DNA and analysis of the B cell in the heart tissue of patients with chronic Chagas' heart disease. Dissertation 2001, FU Berlin.
28. Lukitsch I., Kehr J., Chaykovska L., Wallukat G., Nieminen-Kelhä M., Batuman V., et al. Renal ischemia and transplantation predicts pose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 2012, 94:8-13.
29. Wallukat G., Wollenberger A. Involvement of β2-adrenergic receptors in the potentaion of the chronotropic action of isoprenaline evoked in rocker-cultured neonatal rat heart cells by pyruvate and L (+) lactate. Pharmacological aspects of heart disease 1987, 217-231. Martinius Nijhoff Publishing, Boston. R.E. Beamisch, V. Panagia, N.S. Dhalla (Eds.).
30. Jahns R., Boivin V., Krapf T., Wallukat G., Boege F., Lohse M.J. Modulation of β1-adrenoceptor activity by domain-specific antibodies and heart-failure associated autoantibodies. J Am Coll Cardiol 2000, 36:280-1287.
31. Krause E.G., Bartel S., Beyerdörfer I., Wallukat G. Activation of cyclic AMP-dependent protein kinase in cardiomyocytes by anti-β 1-adrenoceptor autoantibodies from patients with idiopathic dilated cardiomyopathy. Blood Press 1996, 37-40. Suppl 3.
32. Christ T., Wetwer E., Dobrew D., Adolph E., Knaut M., Wallukat G., et al. Autoantibodies against the β1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 2001, 33:1280-1287.
33. Wang L., Lu K., Hao H., Li X., Wang J., Wang K., et al. Decreased autophagy in rat heart induced by anti-β1-adrenergic receptor autoantibodies contributes to the decline in mitochondrial membrane potential. PLoS One 2013, 8:e81296.
34. Staudt Y., Mobini R., Fu M., Felix S.B., Kuhn J.P., Staudt A. β1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 2003, 466:1-6.
35. Jane-wit D., Alfuntas C.Z., Johnson J.M., Yong S., Wickley P.J., Wang C., et al. β1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007, 116:399-410.
36. Liu J., Mao W., Iwai C., Fukuoka S., Vulapalli R., Huang H., et al. Adoptive passive transfer of rabbit β1-adrenoceptor peptide immune cardiomyopathy into the Rag2-/- mouse: participation of the ER stress. J Mol Cell Cardiol 2008, 44:304-314.
37. Haberland A., Wallukat G., Dahmen C., Kage A., Schimke I. Aptamer neutralization of β1-adrenoceptror autoantibodies isolated from patients with cardiomyopathies. Circ Res 2011, 109:986-992.
38. Okruhlikova L., Morwinski R., Schulze W., Bartel S., Weismann P., Tribulova N., et al. Autoantibodies against G-protein coupled receptors modulate heart mast cells. Cell Mol Immunol 2007, 4:127-133.
39. Tutor A.S., Penela P., Mayor F. Anti-β1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Cardiovasc Res 2007, 76:51-60.
40. Du Y., Yan L., Wang J., Zhan W., Song K., Han X., et al. β1-Adrenoceptor autoantibodies from DCM patients enhance the proliferation of T lymphocytes through the β1-AR/cAMP/PKA and p38 MAPK pathways. PLoS One 2012, 7:e52911.
41. Herse F., LaMarca B. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol 2013, 69:413-418.
42. Günther J., Kill A., Becker M.O., Heidecke H., Rademacher J., Siegert E., et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 2014, 16:R65. doi: 0.1186/ar4503.
43. Wallukat G., Morwinski R., Kowal K., Förster A., Boewer V., Wollenberger A. Autoantibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: ß-adrenergic agonism without desensitization. Eur Heart J 1991, 12(Suppl. D):178-181.
44. Wallukat G., Fu M.L.X., Magnusson Y., Hjalmarson A., Hoebeke J., Wollenberger A. Agonistic effects of anti-peptide antibodies and autoantibodies against adrenergic and cholinergic receptors: absence of desensitization. Blood Press 1996, 5:31-36.
45. Wallukat G., Fu H.M., Matsui S., Hjalmarson Å., Fu M.L. Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitizing agonist-like effects. Life Sci 1999, 64:465-469.
46. Bornholz B., Weidtkamp-Peters S., Schmitmeier S., Seidel C.A., Herda L.R., Felix S.B., et al. Impact of human autoantibodies on β1-adrenergic receptor conformation, activity, and internalization. Cardiovasc Res 2013, 97:472-480.
47. Matsui S., Fu M.L.X., Katsuda S., Hayase M., Yamaguchi N., Teraoka K., et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997, 29:641-655.
48. Jahns R., Boivin V., Hein L., Triebel S., Angermann C.E., Ertl G., et al. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004, 113:1419-1429.
49. Matsui S., Fu M., Hayase M., Katsuda S., Yamaguchi N., Teraoka K., et al. Transfer of rabbit autoimmune cardiomyopathy into severe combined immunodeficiency mice. J Cardiovasc Pharmacol 2003, 42(Suppl. 1):99-103.
50. Omerovic E., Bollano E., Andersson B., Kujacic V., Schulze W., Hjalmarson Å., et al. Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity 2000, 32:271-280.
51. Li H., Scherlag B.J., Kem D.C., Benbrook A., Shen X., Cunningham M.W., et al. Inducible cardiac arrhythmias caused by enhanced β1-adrenergic autoantibody expression in the rabbit. Am J Physiol Heart Circ Physiol 2014, 306:H422-H428.
52. Dandel M., Wallukat G., Englert A., Lehmkuhl H.B., Knosalla C., Hetzer R. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail 2012, 14:1374-1388.
53. Satta N., Vuilleumier N. Auto-antibodies as possible markers and mediators of ischemic, dilated, and rhythmic cardiopathies. Curr Drug Targets 2015, 16:342-360.
54. Nussinovitch U., Shoenfeld Y. The diagnostic and clinical significance of anti-muscarinic receptor autoantibodies. Clin Rev Allergy Immunol 2012, 423:298-308.
55. Wallukat G., Munoz-Saravia S.G., Haberland A., Bartel S., Araujo R., Valda G., et al. Distinct pattern of autoantibodies against G-protein coupled receptors in Chagas' cardiomyopathy and megacolon. J Am Coll Cardiol 2010, 55:463-468.
56. Nikolaev V.O., Boivin V., Störk S., Angermann C.E., Ertl G., Lohse M.J., et al. A novel fluorescence method for the rapid detection of functional β1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007, 50:423-431.
57. Talvani A., Rocha M.O., Ribeiro A.L., Borda E., Sterin-Borda L., Teixeira M.M. Levels of anti-M2 and anti-β1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas' heart disease. Microbes Infect 2006, 8:2459-2464.
58. Wallukat G., Wollenberger A., Morwinski R., Pitschner H.F. Anti-β1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995, 27:397-406.
59. Ferrari I., Levin M.J., Wallukat G., Elies R., Lebesgue D., Chiale P., et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human β 1-adrenergic receptor. J Exp Med 1995, 182:59-65.
60. Förster O.A.E.M. Peripartum cardiomyopathy-an autoimmune disease. Thesis, Faculty of Health Sciences 2007, University Witwatersrand, Johannesburg. http://wiredspace.wits.ac.za/bitstream/handle/10539/5011/PhD%20Thesis%20final.pdf?sequence=1.
61. Liu J., Wang Y., Chen M., Zhao W., Wang X., Wang H., et al. The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. PLoS One 2014, 9(1):e86770.
62. Chiale P.A., Rosenbaum M.B., Elizari M.V., Hjalmarson Å., Magnusson Y., Wallukat G., et al. High prevalence of antibodies against β1- and β2-adrenoceptors in patients with primary electrical abnormalities. J Am Coll Cardiol 1995, 26:864-869.
63. Brisinda D., Sorbo A.R., Venuti A., Ruggieri M.P., Manna R., Fenici P., et al. Anti-β-adrenoceptor autoimmunity causing idiopathic arrhythmias and cardiomyopathy. Circ J 2012, 76:1345-1353.
64. Iwata M., Yoshikawa T., Baba A., Anzai T., Mitamura H., Ogawa S. Autoantibodies against the second extracellular loop of the β1-adrenergic receptor predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001, 37:418-424.
65. Segovia M., Ganzinelli S., Reina S., Borda E., Sterin-Borda L. Role of anti-β1 adrenergic antibodies from patients with periodontitis in cardiac dysfunction. J Oral Pathol Med 2012, 41:242-248.
66. Muñoz Saravia S.G., Haberland A., Bartel S., Araujo R., Valda G., Duchen D., et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon: their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 2010, 56:526-527.
67. Tarleton R.L. Chagas disease: a role for autoimmunity?. Trends Parasitol 2003, 19:447-451.
68. Medei E.H., Nascimento J.H., Pedrosa R.C., Carvalho A.C. Role of autoantibodies in the physiopathology of Chagas' disease. Arq Bras Cardiol 2008, 91:257-262.
69. Wallukat G., Haberland A., Schimke I. A vision of future treatment in chagas heart disease. J Am Coll Cardiol 2014, 63:1027.
70. Haberland A., Wallukat G., Berg S., Schulz A.M., Freyse E.J., Vetter R., et al. Neutralization of pathogenic β1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats. Mol Cell Biochem 2014, 393:177-180.
71. Wallukat G., Müller J., Haberland A., Berg S., Schulz A., Freyse E.J., et al. Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: a vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies. Atherosclerosis 2015, 244:44-47.
72. Jünnemann A.G.M., Kunze R., Bellios N., Wallukat G., Herrmann M., Rech J. Stimulatory autoantibodies against β2-adrenergic receptors in open-angle glaucoma IV: effect of immunoadsorption on antibody level and intraocular pressure. Eur J Ophthalmol 2011, 10.5301/ejo.2011.7835.
73. Kunze R., Wallukat G., Rosenthal P., Straube R. Peptides have binding affinities to an antibody which recognize an epitope on an β1-loop2 and β2-loop1 of an adrenoceptor 2009, WO/2009/090227, EP 2244718-AZ.
74. Karczewski P., Hempel P., Kunze R., Bimmler M. Agonistic autoantibodies to the β1-adrenergic and the β2-adrenergic receptor in Alzheimer's and vascular dementia. Scand J Immunol 2012, 75:524-530.
75. Kohr D., Singh P., Tschernatsch M., Kaps M., Pouokam E., Diener M., et al. Autoimmunity against the β2-adrenergic receptor and muscarinic M2 receptor in complex regional pain syndrome. Pain 2011, 152:2690-2700.
76. Wallukat G., Wollenberger A. Autoantibodies to β2-adrenergic receptors with antiadrenergic activity from patients with allergic asthma. J Allergy Clin Immunol 1991, 88:581-587.
77. Li M.X., Wang X.L., Tang J.N., Liu X.J., Tian J., Yan L., et al. Distribution and property of anti-β3-adrenoceptor autoantibody in patients with heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2005, 33:1114-1118.
78. Wang J., Li M., Ma X., Bai K., Wang L., Yan Z., et al. Autoantibodies against the β3-adrenoceptor protect from cardiac dysfunction in a rat model of pressure overload. PLoS One 2013, 8:e78207.
79. Wang J., Ma X., Zhang Y., Wang H., Yang J., Dong J., et al. Cardiac protective effect of the autoantibody against β3-adrenoceptor in rats with experimental heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2014, 42:424-427.
80. Fu M.L., Herlitz H., Wallukat G., Hilme E., Hedner T., Hoebeke J., et al. Functional autoimmune epitope on β1-adrenergic receptors in patients with malignant hypertension. Lancet 1994, 344:1660-1663.
81. Wallukat G., Dandel M., Müller J., Bartel S., Schulze W., Hetzer R. Agonistic autoantibodies against the endothelin 1 ETA and β1-adrenergic receptor in sera of patients with idiopathic pulmonary arterial hypertension. Circulation 2007, 116:II503.
82. Dandel M., Wallukat G., Englert A., Lehmkuhl H., Hetzer R. Functional autoantibodies against G-protein coupled receptors in sera of patients with pulmonary arterial hypertension: potential involvement in the pathogenesis of the disease. J Am Coll Cardiol 2009, 53(Suppl. A454).
83. Wenzel K., Haase H., Wallukat G., Derer W., Bartel S., Hohmuth V., et al. Potential relevance of β1-adrenergic receptor autoantibodies in refractory hypertension. PLoS One 2008, 3(11):e3742.
84. Luther H.P., Homuth V., Wallukat G. β1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension 1997, 29:678-682.
85. Hempel P., Karczewski P., Kohnert K.D., Raabe J., Lemke B., Kunze R., et al. Sera of patients with type2 diabetes contains agonistic autoantibodies against G-protein coupled receptors. Scand J Immunol 2009, 70:159-160.
86. Karczewski P., Haase H., Hempel P., Bimmler M. Agonistic antibody to the β1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol Cell Biol 2010, 333:233-242.
87. Karczewski P., Pohlmann A., Wagenhaus B., Wisbrun N., Hempel P., Lemke B., et al. Antibodies to the β1-adrenergic receptor cause vascular impairments in the rat brain as demonstrated by magnetic resonance angiography. PLoS One 2012, 7(7):e 41602.
88. Haberland A., Santos R.A.S., Schimke I., Wallukat G. Are agonistic autoantibodies against G-protein coupled receptors involved in the development of long-term side effects of tumor chemotherapy?. Case Rep Oncol 2013, 6:104-108.
89. Wallukat G., Homuth V., Fischer T., Lindschau C., Horstkamp B., Jüpner A., et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999, 103:945-952.
90. Dechend R., Homuth V., Wallukat G., Kreuzer J., Park J.K., Theuer J., et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000, 101:2382-2387.
91. Dechend R., Viedt C., Müller D.N., Ugele B., Brandes R.P., Wallukat G., et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003, 107:1632-1639.
92. Bobst S.M., Day M.C., Gilstrap L.C., Xia Y., Kellems R.E. Maternal autoantibodies from preeclamptic patients activate angiotensin receptor on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-I secretion. Am J Hypertens 2005, 18:330-336.
93. Dörffel Y., Wallukat G., Bochnig N., Homuth V., Herberg M., Dörffel W., et al. Agonistic AT1 receptor autoantibodies and monocyte stimulation in hypertensive patients. Am J Hypertens 2003, 16:827-833.
94. Fu M.L., Herlitz H., Schulze W., Wallukat G., Micke P., Eftekhari P., et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000, 18:945-953.
95. Albert C., von Schultzendorff M., Şalaru D., Halloul Z., Dragun D., Heidecke H., et al. In arterial occlusive disease autoantibodies against ETAR and AT(1)R correlate with each other but are not associated with classical cardiovascular risk factors. Vasa 2014, 43:113-123.
96. Dragun D., Müller D.M., Bräsen J.H., Fritsche L., Nieminen-Kelhä M., Dechend R., et al. Angiotensin II type receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
97. Riemekasten G., Philippe A., Näther M., Slowinski T., Müller D.N., Heidecke H., et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011, 70:530-536.
98. Günther J., Rademacher J., van Laar J.M., Siegert E., Riemekasten G. Functional autoantibodies in systemic sclerosis. Semin Immunopathol 2015, 37:529-542.
99. Fu M.L. Anti-M2 muscarinic receptor autoantibodies and idiopathic dilated cardiomyopathy. Int J Cardiol 1996, 54:127-135.
100. Wallukat G., Nissen E., Morwinski R., Müller J. Autoantibodies against the β-and muscarinic receptors in cardiomyopathy. Herz 2000, 25:261-266.
101. Goin J.C., Leiros C.P., Borda E. Sterin-Borda. Interaction of human chagasic IgG with the second extracellular loop of the human muscarinic acetylcholine receptor: functional and pathological implication. FASEB J 1997, 11:77-83.
102. Koo N.Y., Hwang S.M., Choi S.Y., Kim B., Kho H.S., Choi S.Y., et al. Functional epitope of muscarinic type 3 receptor which interact with autoantibodies from Sjögren's syndrome patients. Rheumatology 2008, 47:828-833.
103. Jin M., Hwang S.M., Koo N.Y., Kim B., Kho H.S., Choi S.Y., et al. Autoantibodies in Sjögren's syndrome patients acutely inhibit muscarinic receptor function. Oral Dis 2012, 18:132-139.
104. Lee B.H., Gauna A.E., Perez G., Park Y.J., Pauley K.M., Kawai T., et al. Autoantibodies against muscarinic type 3 receptor in Sjögren's syndrome inhibit aquaporin 5 trafficking. PLoS One 2013, 8(1):e53113.
105. Sumida T., Tsuboi H., Iizuka M., Hirota T., Asashima H., Matsumoto I. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review. J Autoimmun 2014, 51:44-50.
106. Li H., Kem D.C., Reim S., Khan M., Vanderlinde-Wood M., Zillner C., et al. Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism. Hypertension 2012, 59:402-408.
107. Peter J.C., Nicholson J.R., Heydet D., Lecourt A.C., Hoebeke J., Hofbauer K.G. Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo. Am J Physiol Regul Integr Comp Physiol 2007, 292:R2151-R2158.
108. Peter J.C., Bekel A., Lecourt A.C., Zipfel G., Eftekhari P., Nesslinger M., et al. Anti-melanocortin-4 receptor autoantibodies in obesity. J Clin Endocrinol Metab 2009, 94:793-800.
109. Störk S., Boivin V., Horf R., Hein L., Lohse M.J., Angermann C.E., et al. Stimulating autoantibodies directed against the cardiac β1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006, 152:697-704.
110. Jahns R., Boege F. Questionable validity of peptide-based ELISA strategies in the diagnostics of cardiopathogenic autoantibodies that activate G-protein-coupled receptors. Cardiology 2015, 131:149-150.
111. Jahns R., Boivin V., Siegmund C., Inselmann G., Lohse M.J., Boege F. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999, 99:649-654.
112. Holthoff H.P., Zeibig S., Jahns-Boivin V., Bauer J., Lohse M.J., Kääb S., et al. Detection of anti β1-ar auto-antibodies in heart failure by a cell-based competition ELISA. Circ Res 2012, 111:675-684.
113. Wallukat G., Wollenberger A. Cultivated cardiac muscle cells-a functional test system for the detection of autoantibodies against the β-adrenergic receptor. Acta Histochem Suppl 1988, 35:145-149.
114. Wallukat G., Nisson E. Anti-β(1)-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures - comparison of methods. Cell Dev Biol 2001, 37:175-176.
115. Nguemo F., Saric T., Pfannkuche K., Watzele M., Reppel M., Hescheler J. In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cellular physiology and biochemistry. Int J Cell Phys Biochem Pharmacol 2012, 29:819-832.
116. Preuss B., Tunaru S., Henes J., Offermann S., Klein R. A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients' sera. Immunology 2014, 177:179-189.
117. http://www.discoverx.com/targets/gpcr-target-biology.
118. Li H., Yu X., Liles C., Khan M., Vanderlinde-Wood M., Galloway A., et al. Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc 2014, 3:e000755. 10.1161/JAHA.113.000755).
119. Dahmen C., Haberland A., Kage A., Schimke I., Wallukat G. Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human β-1-adrenergic receptor 2011, PCT/EP2011/060572, WO2012000889 A1.
120. Schimke I., Haberland A., Wallukat G.. Use of aptamers in therapy and/or diagnosis of autoimmune diseases. EP2497828A1, WO2012119938A2, 2012; US 9234201 B2, 2016.
121. Roggenbuck D., Hiemann R., Bogdanos D., Reinhold D., Conrad K. Standardization of automated interpretation of immunofluorescence tests. Clin Chim Acta 2013, 421:168-169.
122. Hiemann R., Buttner T., Krieger T., Roggenbuck D., Sack U., Conrad K. Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmun Rev 2009, 9:17-22.
123. Hekman M., Feder D., Keenan A.K., Gal A., Klein H.W., Pfeuffer T., et al. Reconstitution of β-adrenergic receptor with components of adenylate cyclase. EMBO J 1984, 3:3339-3345.
124. Bornholz B., Benninghaus T., Reinke Y., Felix S.B., Roggenbuck D., Jahns-Boivin V., et al. A standardised FACS assay based on native, receptor transfected cells for the clinical diagnosis and monitoring of β1-adrenergic receptor autoantibodies in human heart disease. Clin Chem Lab Med 2016, 54:683-691.
125. Bornholz B., Hanzen B., Reinke Y., Felix S.B., Jahns R., Schimke I., et al. Detection of DCM-associated β1-adrenergic receptor autoantibodies requires functional readouts or native human β1-receptors as targets. Int J Cardiol 2015, 202:728-730.